COGNITION THERAPEUTICS INC
About COGNITION THERAPEUTICS INC
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$23.5M
- Total assets
- $48.4M
- Market cap
- $115.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $47.8M
- Operating income
- -$47.8M
- Income tax
- $0
- Net income
- -$23.5M
- EPS (basic)
- $-0.32
- EPS (diluted)
- $-0.32
Balance sheet
- Total assets
- $48.4M
- Current assets
- $48.0M
- Total liabilities
- $14.1M
- Current liabilities
- $13.9M
- Shareholders’ equity
- $34.3M
Cash flow
- Operating cash flow
- -$24.6M
- Investing cash flow
- $9.0K
- Financing cash flow
- $36.6M
- Net cash flow
- $12.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $115.5M
- EPS (diluted)
- $-0.32
- Shares outstanding
- 101.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 8, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $23.5M.
- Trading 64% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review COGNITION THERAPEUTICS INC.
Write a review
News about COGNITION THERAPEUTICS INC
News & sentiment via Polygon.io
